Voyager Therapeutics, a clinical-stage gene therapy company based in Lexington, Massachusetts, focuses on developing treatments for severe neurological diseases, including Alzheimer's and ALS. Founded in 2015, it employs 162 people and utilizes its TRACER AAV platform for therapy development.
Voyager Therapeutics (VYGR) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Voyager Therapeutics's actual EPS was -$0.53, missing the estimate of -$0.46 per share, resulting in a -15.72% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
